Proposal Number | | | | | Vote Required for Approval | | | Effect of Abstentions | | | Effect of Broker Non-Votes, If Any | | |
1 | | | Election of Class II director | | | | | Under plurality voting, there are no | | | None | | |
2 | | | Advisory approval of the compensation of our named executive officers | | | “ | | | Against | | | None | |
3 | | | Ratification of the selection of Ernst & Young LLP as the Company’s independent auditor for | | | “ | | | Against | | | None | |
4 | | | Approval of an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock | | | “FOR” votes from the majority of votes cast on the matter | | | None | | | None | |
Name | | Audit | | Compensation | | Nominating and Corporate Governance | | | Audit | | Compensation | | Nominating and Corporate Governance | | ||||||||||||||||||||||||
Bryan Giraudo | | | | X | | | | | — | | | | | X* | | | | | | X | | | | | | | | | | X* | | | ||||||
Sarah Noonberg, M.D., Ph.D.(1) | | | | X | | | | | — | | | | | — | | | ||||||||||||||||||||||
Sarah A. O’Dowd | | | | — | | | | | — | | | | | X | | | | | | | | | | | | | | | | X | | | ||||||
Dinesh V. Patel, Ph.D. | | | | — | | | | | — | | | | | — | | | | | | | | | | | | | | | | | | | ||||||
Harold E. Selick, Ph.D. | | | | — | | | | | X* | | | | | X | | | | | | | | | | | X* | | | | | X | | | ||||||
Daniel N. Swisher, Jr.(1) | | | | X | | | | | | | | | | | | | ||||||||||||||||||||||
William D. Waddill | | | | X* | | | | | X | | | | | — | | | | | | X* | | | | | X | | | | | | | | ||||||
Lewis T. Williams, M.D., Ph.D. | | | | — | | | | | X | | | | | — | | | | | | | | | | | X | | | | | | | | ||||||
Total meetings in fiscal 2022 | | | | 6 | | | | | 3 | | | | | 4 | | | ||||||||||||||||||||||
Total meetings in fiscal 2023 | | | | 5 | | | | | 4 | | | | | 1 | | |
| Board Diversity Matrix (as of | |
| Total number of directors – 7 | |
Gender identity: | | Female | | Male | | Non- Binary | | Did not Disclose Gender | | | Female | | Male | | Non- Binary | | Did not Disclose Gender | | ||||||||||||||||||||||||||||||||
Directors | | | | 2 | | | | | 5 | | | | | — | | | | | — | | | | | | 1 | | | | | 6 | | | | | — | | | | | — | | | ||||||||
Number of directors who identify in any of the categories below: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
African American or Black | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Alaskan Native or Native American | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Asian | | | | — | | | | | 1 | | | | | — | | | | | — | | | | | | — | | | | | 1 | | | | | — | | | | | — | | | ||||||||
Hispanic or Latinx | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Native Hawaiian or Pacific Islander | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
White | | | | 2 | | | | | 4 | | | | | — | | | | | — | | | | | | 1 | | | | | 5 | | | | | — | | | | | — | | | ||||||||
Two or More Races or Ethnicities | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
LGBTQ+ | | | | — | | | | | — | | | | | — | | | | | — | | | | 1 | |
| | Fiscal Year Ended December 31, | | | Fiscal Year Ended December 31, | | ||||||||||||||||||||
| | 2022 | | 2021 | | | 2023 | | 2022 | | ||||||||||||||||
Audit Fees(1) | | | $ | 1,035,150 | | | | $ | 1,507,376 | | | | | $ | 1,622,000 | | | | $ | 1,035,150 | | | ||||
Audit-Related Fees(2) | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees(3) | | | | 20,639 | | | | | 27,605 | | | | | | 35,806 | | | | | 20,639 | | | ||||
All Other Fees(4) | | | | 3,405 | | | | | — | | | | | | 7,200 | | | | | 3,405 | | | ||||
Total Fees | | | $ | 1,059,194 | | | | $ | 1,534,981 | | | | | $ | 1,665,006 | | | | $ | 1,059,194 | | |
| | | Number of Shares of Common Stock | | |||
Authorized for issuance | | | | | 90,000,000 | | |
Issued and outstanding | | | | | 58,643,133 | | |
Reserved for issuance | | | | | 16,085,529 | | |
• Available for future grant under employee equity incentive plans* | | | | | 3,444,761 | | |
• Outstanding awards under our employee equity incentive plans* | | | | | 10,020,508 | | |
• Outstanding warrants | | | | | 2,620,260 | | |
Total share usage (issued and outstanding + reserved for issuance) | | | | | 74,728,662 | | |
Total share usage as a percentage of authorized | | | | | 83% | | |
Name | | | Age | | | Position | | |||
Dinesh V. Patel, Ph.D. | | | | | | | | President, Chief Executive Officer and Director | | |
Asif Ali | | | | | | | | Executive Vice President, Chief Financial Officer | | |
Suneel Gupta, Ph.D. | | | | | | | | Chief Development Officer | | |
Arturo Molina, M.D., M.S., F.A.C.P. | | | | | | | | Chief Medical Officer | |
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
Farallon Partners, L.L.C. and its affiliated entities(2) | | | | | 5,151,887 | | | | | | 9.7% | | |
Biotechnology Value Fund, L.P. and its affiliated entities(3) | | | | | 5,025,900 | | | | | | 9.5% | | |
State Street Corporation and its affiliated entities(4) | | | | | 3,792,926 | | | | | | 7.4% | | |
BlackRock, Inc.(5) | | | | | 3,652,157 | | | | | | 7.1% | | |
RTW Investments, L.P.(6) | | | | | 3,591,986 | | | | | | 7.0% | | |
The Vanguard Group, Inc.(7) | | | | | 3,097,714 | | | | | | 6.0% | | |
Citadel Advisors LLC and its affiliated entities(8) | | | | | 2,682,814 | | | | | | 5.2% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Dinesh V. Patel, Ph.D.(9) | | | | | 1,706,580 | | | | | | 3.2% | | |
Suneel Gupta, Ph.D.(10) | | | | | 354,461 | | | | | | * | | |
David Y. Liu, Ph.D.(11) | | | | | 483,479 | | | | | | * | | |
Harold E. Selick, Ph.D.(12) | | | | | 153,520 | | | | | | * | | |
Bryan Giraudo(13) | | | | | 106,500 | | | | | | * | | |
Sarah Noonberg, M.D., Ph.D.(14) | | | | | 80,100 | | | | | | * | | |
Sarah A. O’Dowd(15) | | | | | 53,000 | | | | | | * | | |
William D. Waddill(16) | | | | | 113,475 | | | | | | * | | |
Lewis T. Williams, M.D., Ph.D.(17) | | | | | 88,500 | | | | | | * | | |
All current executive officers and directors as a group (10 persons)(18) | | | | | 2,681,916 | | | | | | 5.0% | | |
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
5% Stockholders: | | | | | | | | | | | | | |
Farallon Partners, L.L.C. and its affiliated entities(2) | | | | | 5,798,340 | | | | | | 9.9% | | |
Biotechnology Value Fund, L.P. and its affiliated entities(3) | | | | | 5,798,340 | | | | | | 9.9% | | |
BlackRock, Inc.(4) | | | | | 5,543,902 | | | | | | 9.5% | | |
RTW Investments, L.P.(5) | | | | | 5,315,514 | | | | | | 9.1% | | |
The Vanguard Group, Inc.(6) | | | | | 3,153,916 | | | | | | 5.4% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Dinesh V. Patel, Ph.D.(7) | | | | | 1,959,780 | | | | | | 3.3% | | |
Suneel Gupta, Ph.D.(8) | | | | | 471,030 | | | | | | * | | |
Asif Ali(9) | | | | | 59,108 | | | | | | * | | |
Harold E. Selick, Ph.D.(10) | | | | | 204,586 | | | | | | * | | |
Bryan Giraudo(11) | | | | | 157,566 | | | | | | * | | |
Sarah A. O’Dowd(12) | | | | | 106,566 | | | | | | * | | |
Daniel N. Swisher, Jr.(13) | | | | | 7,500 | | | | | | * | | |
William D. Waddill(14) | | | | | 151,566 | | | | | | * | | |
Lewis T. Williams, M.D., Ph.D.(15) | | | | | 139,566 | | | | | | * | | |
All current executive officers and directors as a group (10 persons)(16) | | | | | 3,323,142 | | | | | | 5.4% | | |
Non-Equity Principal Position | | Year | | Salary ($)(1) | | Stock Awards ($)(2)(3) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(4) | | All Other Compensation ($)(5) | | Total ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Year | | Salary ($)(1) | | Stock Awards ($)(2)(3) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(4) | | All Other Compensation ($)(5) | | Total ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dinesh V. Patel, Ph.D. President and Chief Executive Officer | | | | | 2022 | | | | | 630,000 | | | | | 897,813 | | | | | 4,211,963 | | | | | 242,550 | | | | | 10,912 | | | | | 5,993,238 | | | | | | | 2023 | | | | | 655,200 | | | | | — | | | | | 6,041,100 | | | | | 360,360 | | | | | 10,912 | | | | | 7,067,572 | | | ||||||||||||
| | | 2021 | | | | | 600,000 | | | | | 589,250 | | | | | 3,919,365 | | | | | 429,000 | | | | | 7,118 | | | | | 5,544,733 | | | | | | 2022 | | | | | 630,000 | | | | | 897,813 | | | | | 4,211,963 | | | | | 242,550 | | | | | 10,912 | | | | | 5,993,238 | | | |||||||||||||||
Suneel Gupta, Ph.D. Chief Development Officer | | | | | 2022 | | | | | 500,000 | | | | | 359,125 | | | | | 1,684,785 | | | | | 130,000 | | | | | 10,894 | | | | | 2,684,804 | | | | | | | 2023 | | | | | 515,205 | | | | | 251,006 | | | | | 1,245,977 | | | | | 193,125 | | | | | 10,876 | | | | | 2,216,189 | | | ||||||||||||
| | | 2021 | | | | | 455,000 | | | | | 282,840 | | | | | 1,393,552 | | | | | 236,600 | | | | | 7,118 | | | | | 2,375,110 | | | | | | 2022 | | | | | 500,000 | | | | | 359,125 | | | | | 1,684,785 | | | | | 130,000 | | | | | 10,894 | | | | | 2,684,804 | | | |||||||||||||||
David Y. Liu, Ph.D. Former Chief Research and Development Strategy Officer (6) | | | | | 2022 | | | | | 475,000 | | | | | 287,300 | | | | | 1,347,828 | | | | | 123,500 | | | | | 15,178 | | | | | 2,248,806 | | | |||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2021 | | | | | 455,000 | | | | | 235,700 | | | | | 1,132,261 | | | | | 233,188 | | | | | 14,678 | | | | | 2,070,827 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Asif Ali EVP, Chief Financial Officer (6) | | | | 2023 | | | | | 447,000 | | | | | 129,306 | | | | | 641,867 | | | | | 178,800 | | | | | 5,242 | | | | | 1,402,215 | | |
Name | | 2022 Base Salary ($) | | Target Bonus (as a% of base salary) | | Amount of Bonus Earned ($) | | | 2023 Base Salary ($) | | Target Bonus (As a % of Base Salary) | | Amount of Bonus Earned ($) | | ||||||||||||||||||||||||
Dinesh V. Patel, Ph.D. | | | | 630,000 | | | | | 55% | | | | | 242,550 | | | | | | 655,200 | | | | | 55% | | | | | 360,360 | | | ||||||
Suneel Gupta, Ph.D. | | | | 500,000 | | | | | 40% | | | | | 130,000 | | | | | | 515,205 | | | | | 40% | | | | | 193,125 | | | ||||||
David Y. Liu, Ph.D. | | | | 475,000 | | | | | 40% | | | | | 123,500 | | | ||||||||||||||||||||||
Asif Ali | | | | 447,500 | | | | | 40% | | | | | 178,800 | | |
| | Option Awards | | Stock Awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Equity Incentive Plan Awards: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Equity Incentive Plan Awards | | ||||||||||||||||||||||||||||||||||||
| | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Vesting Commencement Date | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Yet Vested ($) | | | Grant Date | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Vesting Commencement Date | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#) | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Yet Vested ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dinesh V. Patel, Ph.D. | | | | | 04/29/2016 | | | | | 60,000 | | | | | — | | | | $ | 4.21 | | | | | 04/25/2016 | | | | | 04/28/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | 04/29/2016 | | | | | 54,000 | | | | | — | | | | $ | 4.21 | | | | | 04/25/2016 | | | | | 04/28/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||
| | | 10/11/2016 | | | | | 320,000 | | | | | — | | | | $ | 21.58 | | | | | 08/10/2016 | | | | | 10/10/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 10/11/2016 | | | | | 320,000 | | | | | — | | | | $ | 21.58 | | | | | 08/10/2016 | | | | | 10/10/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/28/2018 | | | | | 150,000 | | | | | — | | | | $ | 16.95 | | | | | 02/28/2018 | | | | | 02/27/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 02/28/2018 | | | | | 150,000 | | | | | — | | | | $ | 16.95 | | | | | 02/28/2018 | | | | | 02/27/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 08/15/2018 | | | | | 54,700 | | | | | — | | | | $ | 8.58 | | | | | 08/05/2018 | | | | | 08/14/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 08/15/2018 | | | | | 54,700 | | | | | — | | | | $ | 8.58 | | | | | 08/05/2018 | | | | | 08/14/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/28/2019(1)(2) | | | | | 165,312 | | | | | 7,188 | | | | $ | 8.02 | | | | | 02/28/2019 | | | | | 02/27/2029 | | | | | 7,188 | | | | | 78,421 | | | | | — | | | | | — | | | | | | 02/28/2019(1) | | | | | 172,500 | | | | | — | | | | $ | 8.02 | | | | | 02/28/2019 | | | | | 02/27/2029 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/28/2020(1) | | | | | 166,458 | | | | | 68,542 | | | | $ | 7.80 | | | | | 02/28/2020 | | | | | 02/27/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 02/28/2020(1) | | | | | 225,208 | | | | | 9,792 | | | | $ | 7.80 | | | | | 02/28/2020 | | | | | 02/27/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/26/2021(1)(3)(4) | | | | | 103,125 | | | | | 121,875 | | | | $ | 23.57 | | | | | 02/26/2021 | | | | | 02/25/2031 | | | | | 25,000 | | | | | 272,750 | | | | | 25,000 | | | | | 272,750 | | | | | | 02/26/2021(1)(2)(3) | | | | | 159,375 | | | | | 65,625 | | | | $ | 23.57 | | | | | 02/26/2021 | | | | | 02/25/2031 | | | | | 25,000 | | | | | 573,250 | | | | | 25,000 | | | | | 573,250 | | | |||||||||||||||||||||
| | | 02/15/2022(1)(5) | | | | | 39,062 | | | | | 148,438 | | | | $ | 28.73 | | | | | 02/15/2022 | | | | | 02/14/2032 | | | | | 31,250 | | | | | 340,938 | | | | | — | | | | | — | | | | | | 02/15/2022(1)(4) | | | | | 85,937 | | | | | 101,563 | | | | $ | 28.73 | | | | | 02/15/2022 | | | | | 02/14/2032 | | | | | 20,834 | | | | | 477,724 | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 05/31/2022(6) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 30,000 | | | | | 327,300 | | | | | | 01/16/2023(1) | | | | | 137,500 | | | | | 462,500 | | | | $ | 12.17 | | | | | 01/16/2023 | | | | | 01/15/2033 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
Suneel Gupta, Ph.D. | | | | | 01/15/2019(7) | | | | | 67,708 | | | | | 2,292 | | | | $ | 7.38 | | | | | 01/07/2019 | | | | | 01/14/2029 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | 01/15/2019 | | | | | 50,000 | | | | | — | | | | $ | 7.38 | | | | | 01/07/2019 | | | | | 01/14/2029 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||
| | | 02/28/2019(1)(2) | | | | | 43,125 | | | | | 1,875 | | | | $ | 8.02 | | | | | 02/28/2019 | | | | | 02/27/2029 | | | | | 1,875 | | | | | 20,456 | | | | | — | | | | | — | | | | | | 02/28/2019(1) | | | | | 45,000 | | | | | — | | | | $ | 8.02 | | | | | 02/28/2019 | | | | | 02/27/2029 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/28/2020(1) | | | | | 60,208 | | | | | 27,792 | | | | $ | 7.80 | | | | | 02/28/2020 | | | | | 02/27/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 02/28/2020(1) | | | | | 81,458 | | | | | 3,542 | | | | $ | 7.80 | | | | | 02/28/2020 | | | | | 02/27/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 02/26/2021(1)(3)(4) | | | | | 36,666 | | | | | 43,334 | | | | $ | 23.57 | | | | | 02/26/2021 | | | | | 02/25/2031 | | | | | 12,000 | | | | | 130,920 | | | | | 12,000 | | | | | 130,920 | | | | | | 02/26/2021(1)(2)(3) | | | | | 56,666 | | | | | 23,334 | | | | $ | 23.57 | | | | | 02/26/2021 | | | | | 02/25/2031 | | | | | 12,000 | | | | | 275,160 | | | | | 12,000 | | | | | 275,160 | | | |||||||||||||||||||||
| | | 02/15/2022(1)(5) | | | | | 15,625 | | | | | 59,375 | | | | $ | 28.73 | | | | | 02/15/2022 | | | | | 02/14/2032 | | | | | 12,000 | | | | | 136,375 | | | | | — | | | | | — | | | | | | 02/15/2022(1)(4) | | | | | 34,375 | | | | | 40,625 | | | | $ | 28.73 | | | | | 02/15/2022 | | | | | 02/14/2032 | | | | | 8,334 | | | | | 191,099 | | | | | — | | | | | — | | | |||||||||||||||||||||
| | | 05/31/2022(6) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 12,000 | | | | | 130,920 | | | | | | 01/16/2023(1)(4) | | | | | 28,359 | | | | | 95,391 | | | | $ | 12.17 | | | | | 01/16/2023 | | | | | 01/15/2033 | | | | | 20,625 | | | | | 472,931 | | | | | — | | | | | — | | | |||||||||||||||||||||
David Y. Liu, Ph.D. | | | | | 10/11/2016 | | | | | 65,000 | | | | | — | | | | $ | 21.58 | | | | | 08/10/2016 | | | | | 10/10/2026 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/28/2018 | | | | | 56,500 | | | | | — | | | | $ | 16.95 | | | | | 02/28/2018 | | | | | 02/27/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 08/15/2018 | | | | | 17,200 | | | | | — | | | | $ | 8.58 | | | | | 08/05/2018 | | | | | 08/14/2028 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/28/2019(1)(2) | | | | | 86,250 | | | | | 3,750 | | | | $ | 8.02 | | | | | 02/28/2019 | | | | | 02/27/2029 | | | | | 3,750 | | | | | 40,913 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/28/2020(1) | | | | | 49,583 | | | | | 20,417 | | | | $ | 7.80 | | | | | 02/28/2020 | | | | | 02/27/2030 | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/26/2021(1)(3)(4) | | | | | 29,791 | | | | | 35,209 | | | | $ | 23.57 | | | | | 02/26/2021 | | | | | 02/25/2031 | | | | | 10,000 | | | | | 109,100 | | | | | 10,000 | | | | | 109,100 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 02/15/2022(1)(5) | | | | | 12,500 | | | | | 47,500 | | | | $ | 28.73 | | | | | 02/15/2022 | | | | | 02/14/2032 | | | | | 10,000 | | | | | 109,100 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 05/31/2022(6) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 12,000 | | | | | 130,920 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asif Ali | | | | | 04/18/2022(5)(6) | | | | | 34,375 | | | | | 48,125 | | | | $ | 19.19 | | | | | 04/18/2022 | | | | | 04/17/2032 | | | | | 10,313 | | | | | 236,477 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/2023(1)(4) | | | | | 14,609 | | | | | 49,141 | | | | $ | 12.17 | | | | | 01/16/2023 | | | | | 01/15/2033 | | | | | 10,625 | | | | | 243,631 | | | | | — | | | | | — | | |
Year | | Summary Compensation Table Total for PEO(1) | | Compensation Actually Paid to PEO(2) | | Average Summary Compensation Table Total for Non-PEO NEOs(3) | | Average Compensation Actually Paid to Non-PEO NEOs(4) | | Value of Initial Fixed $100 Investment Based On Total Shareholder Return(5) | | Net Loss(6) | | | Summary Compensation Table Total for PEO(1) | | Compensation Actually Paid to PEO(2) | | Average Summary Compensation Table Total for Non-PEO NEOs(3) | | Average Compensation Actually Paid to Non-PEO NEOs(4) | | Value of Initial Fixed $100 Investment Based On Total Shareholder Return(5) | | Net Loss(6) | | ||||||||||||||||||||||||||||||||||||||||||||||||
2023 | | | $ | 7,067,572 | | | | $ | 15,327,386 | | | | $ | 1,809,202 | | | | $ | 4,027,890 | | | | $ | 113.74 | | | | $ | (75,955,225) | | | |||||||||||||||||||||||||||||||||||||||||||
2022 | | | $ | 5,993,238 | | | | $ | (5,174,369) | | | | $ | 2,466,805 | | | | $ | (1,687,548) | | | | $ | 54.12 | | | | $ | (127,393,315) | | | | | $ | 5,993,238 | | | | $ | (5,174,369) | | | | $ | 2,466,805 | | | | $ | (1,687,548) | | | | $ | 54.12 | | | | $ | (127,393,315) | | | ||||||||||||
2021 | | | $ | 5,544,733 | | | | $ | 12,111,993 | | | | $ | 2,222,969 | | | | $ | 4,761,991 | | | | $ | 169.64 | | | | $ | (125,550,748) | | | | | $ | 5,544,733 | | | | $ | 12,111,993 | | | | $ | 2,222,969 | | | | $ | 4,761,991 | | | | $ | 169.64 | | | | $ | (125,550,748) | | |
Year | | | Reported Summary Compensation Table Total for PEO | | | Reported Value of Equity Awards(a) | | | Equity Award Adjustments(b) | | | Compensation Actually Paid to PEO | | ||||||||||||
2023 | | | | $ | 7,067,572 | | | | | $ | (6,041,100) | | | | | $ | 14,300,914 | | | | | $ | 15,327,386 | | |
Year | | | Reported Summary Compensation Table Total for PEO | | | Reported Value of Equity Awards(a) | | | Equity Award Adjustments(b) | | | Compensation Actually Paid to PEO | | ||||||||||||
2022 | | | | $ | 5,993,238 | | | | | $ | (5,109,776) | | | | | $ | (6,057,831) | | | | | $ | (5,174,369) | | |
2021 | | | | $ | 5,544,733 | | | | | $ | (4,508,615) | | | | | $ | 11,075,875 | | | | | $ | 12,111,993 | | |
Year | | | Year End Fair Value of Outstanding and Unvested Equity Awards Granted During the Year | | | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | | | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | | | Total Equity Award Adjustments | | |||||||||||||||
2022 | | | | $ | 1,538,304 | | | | | $ | (4,758,042) | | | | | $ | 328,901 | | | | | $ | (3,166,994) | | | | | $ | (6,057,831) | | |
2021 | | | | $ | 5,481,885 | | | | | $ | 2,690,740 | | | | | $ | 1,252,857 | | | | | $ | 1,650,393 | | | | | $ | 11,075,875 | | |
Year | | | Year End Fair Value of Outstanding and Unvested Equity Awards Granted During the Year | | | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | | | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Change in Fair Value from Prior Year End to Vesting Date of Equity Awards Granted in Prior Years that Vested in the Year | | | Total Equity Award Adjustments | | |||||||||||||||
2023 | | | | $ | 7,980,906 | | | | | $ | 2,109,745 | | | | | $ | 2,149,606 | | | | | $ | 2,060,657 | | | | | $ | 14,300,914 | | |
Year | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs | | | Average Reported Value of Equity Awards | | | Average Equity Award Adjustments(a) | | | Average Compensation Actually Paid to Non-PEO NEOs | | ||||||||||||
2022 | | | | $ | 2,466,805 | | | | | $ | (1,839,519) | | | | | $ | (2,314,834) | | | | | $ | (1,687,548) | | |
2021 | | | | $ | 2,222,969 | | | | | $ | (1,522,177) | | | | | $ | 4,061,199 | | | | | | 4,761,991 | | |
Year | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs | | | Average Reported Value of Equity Awards | | | Average Equity Awards Adjustments(a) | | | Average Compensation Actually Paid to Non-PEO NEO | | ||||||||||||
2023 | | | | $ | 1,809,202 | | | | | $ | (1,134,078) | | | | | $ | 3,352,766 | | | | | $ | 4,027,890 | | |
Year | | | Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted During the Year | | | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | | | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | | | Total Average Equity Award Adjustments | | |||||||||||||||
2022 | | | | $ | 553,787 | | | | | $ | (1,661,551) | | | | | $ | 118,408 | | | | | $ | (1,325,478) | | | | | $ | (2,314,834) | | |
2021 | | | | $ | 1,867,101 | | | | | | 1,110,914 | | | | | $ | 403,689 | | | | | $ | 679,495 | | | | | $ | 4,061,199 | | |
Year | | | Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted During the Year | | | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years | | | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Average Change in Fair Value from Prior Year End to Vesting Date of Equity Awards Granted in Prior Years that Vested in the Year | | | Total Average Equity Award Adjustments | | |||||||||||||||
2023 | | | | $ | 1,605,304 | | | | | $ | 686,027 | | | | | $ | 335,868 | | | | | $ | 725,567 | | | | | $ | 3,352,766 | | |
Name | | Fees Earned or Paid in Cash ($) | | Option Awards ($)(1)(2) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Option Awards ($)(1)(2) | | Total ($) | | ||||||||||||||||||||||||
Bryan Giraudo | | | | 60,000 | | | | | 128,940 | | | | | 188,940 | | | | | | 60,000 | | | | | 296,517 | | | | | 356,517 | | | ||||||
Sarah Noonberg, M.D., Ph.D. | | | | 50,000 | | | | | 128,940 | | | | | 178,940 | | | | | | 25,000 | | | | | 591,741 | | | | | 616,741 | | | ||||||
Sarah A. O’Dowd | | | | 45,000 | | | | | 128,940 | | | | | 173,940 | | | | | | 45,000 | | | | | 296,517 | | | | | 341,517 | | | ||||||
Harold E. Selick, Ph.D. | | | | 95,000 | | | | | 128,940 | | | | | 223,940 | | | | | | 98,750 | | | | | 296,517 | | | | | 395,267 | | | ||||||
Daniel N. Swisher, Jr. | | | | 7,174 | | | | | 530,982 | | | | | 538,156 | | | ||||||||||||||||||||||
William D. Waddill | | | | 67,500 | | | | | 128,940 | | | | | 196,440 | | | | | | 67,500 | | | | | 296,517 | | | | | 364,017 | | | ||||||
Lewis T. Williams, M.D., Ph.D. | | | | 47,500 | | | | | 128,940 | | | | | 176,440 | | | | | | 55,000 | | | | | 296,517 | | | | | 351,517 | | |
Name | | | Aggregate Number 2023of Option Awards Outstanding as of December 31, | | |||
Bryan Giraudo | | | | | | | |
Sarah Noonberg, M.D., Ph.D.(1) | | | | | | | |
Sarah A. O’Dowd | | | | | | | |
Harold E. Selick, Ph.D. | | | | | | | |
Daniel N. Swisher, Jr. | | | | | 45,000 | | |
William D. Waddill | | | | | | | |
Lewis T. Williams, M.D., Ph.D. | | | | | | |
Plan Category(1) | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted average exercise price of outstanding options, warrants and rights(6) (b) | | Number of securities remaining available for issuance under equity compensation plans (excluding securities reflected in column (a)) (c) | | | Number of Securities to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a) | | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights(2) (b) | | Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by securities holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
2007 Stock Option and Incentive Plan | | | | 167,828(3) | | | | $ | 3.78 | | | | | — | | | | | | 146,371(3) | | | | $ | 3.89 | | | | | — | | | ||||||
2016 Equity Incentive Plan | | | | 5,914,150(4) | | | | $ | 19.20 | | | | | 1,350,793(7) | | | | | | 7,594,673(4) | | | | $ | 17.10 | | | | | 1,035,798(5) | | | ||||||
2016 Employee Stock Purchase Plan | | | | — | | | | | — | | | | | 1,255,290(8) | | | | | | — | | | | | — | | | | | 1,459,902(6) | | | ||||||
Equity compensation plans not approved by securities holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
2018 Inducement Plan | | | | 995,467(5) | | | | $ | 20.85 | | | | | 574,772 | | | | | | 920,990(8) | | | | $ | 19.56 | | | | | 548,722 | | | ||||||
Total | | | | 7,077,445 | | | | $ | 19.03 | | | | | 3,180,855 | | | | | | 8,662,034 | | | | $ | 17.21 | | | | | 3,044,422 | | |